Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | (R)-9bMS |
Synonyms | |
Therapy Description |
(R)-9bMS inhibits TNK2 (ACK1) and suppresses AR gene expression, potentially leading to decreased tumor cell proliferation and inhibition of tumor growth (PMID: 36861798, PMID: 27902967, PMID: 28609657). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
(R)-9bMS | (R) 9bMS|(R)9bMS|Mahatinib | TNK2 Inhibitor 7 | (R)-9bMS inhibits TNK2 (ACK1) and suppresses AR gene expression, potentially leading to decreased tumor cell proliferation and inhibition of tumor growth (PMID: 36861798, PMID: 27902967, PMID: 28609657). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06705686 | Phase I | (R)-9bMS | Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer (PHAROS) | Not yet recruiting | USA | 0 |